{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:15:50Z","timestamp":1788174950477,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BR 6121\/1-1"],"award-info":[{"award-number":["BR 6121\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>[<jats:sup>18<\/jats:sup>F]fluorodeoxyglucose (FDG) PET and [<jats:sup>123<\/jats:sup>I]metaiodobenzylguanidine (MIBG) scintigraphy may contribute to the differential diagnosis of neurodegenerative parkinsonism. To identify the superior method, we retrospectively evaluated 54 patients with suspected neurodegenerative parkinsonism, who were referred for FDG PET and MIBG scintigraphy. Two investigators visually assessed FDG PET scans using an ordinal 6-step score for disease-specific patterns of Lewy body diseases (LBD) or atypical parkinsonism (APS) and assigned the latter to the subgroups multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal syndrome. Regions-of-interest analysis on anterior planar MIBG images served to calculate the heart-to-mediastinum ratio. Movement disorder specialists blinded to imaging results established clinical follow-up diagnosis by means of guideline-derived case vignettes. Clinical follow-up (1.7\u2009\u00b1\u20092.3 years) revealed the following diagnoses: <jats:italic>n<\/jats:italic>\u2009=\u200919 LBD (<jats:italic>n<\/jats:italic>\u2009=\u200917 Parkinson\u2019s disease [PD], <jats:italic>n<\/jats:italic>\u2009=\u20091\u2009PD dementia, and <jats:italic>n<\/jats:italic>\u2009=\u20091 dementia with Lewy bodies), <jats:italic>n<\/jats:italic>\u2009=\u200931 APS (<jats:italic>n<\/jats:italic>\u2009=\u200928 MSA, <jats:italic>n<\/jats:italic>\u2009=\u20093 PSP), <jats:italic>n<\/jats:italic>\u2009=\u20093 non-neurodegenerative parkinsonism; <jats:italic>n<\/jats:italic>\u2009=\u20091 patient could not be diagnosed and was excluded. Receiver operating characteristic analyses for discriminating LBD vs. non-LBD revealed a larger area under the curve for FDG PET than for MIBG scintigraphy at statistical trend level for consensus rating (0.82 vs. 0.69, <jats:italic>p<\/jats:italic>\u2009=\u20090.06; significant for investigator #1: 0.83 vs. 0.69, <jats:italic>p<\/jats:italic>\u2009=\u20090.04). The analysis of PD vs. MSA showed a similar difference (0.82 vs. 0.69, <jats:italic>p<\/jats:italic>\u2009=\u20090.11; rater #1: 0.83 vs. 0.69, <jats:italic>p<\/jats:italic>\u2009=\u20090.07). Albeit the notable differences in diagnostic performance did not attain statistical significance, the authors consider this finding clinically relevant and suggest that FDG PET, which also allows for subgrouping of APS, should be preferred.<\/jats:p>","DOI":"10.1038\/s41531-020-00141-y","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T11:20:56Z","timestamp":1607685656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-4776","authenticated-orcid":false,"given":"Joachim","family":"Brumberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3833-9822","authenticated-orcid":false,"given":"Nils","family":"Schr\u00f6ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganna","family":"Blazhenets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9377-8935","authenticated-orcid":false,"given":"Lars","family":"Frings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7536-2207","authenticated-orcid":false,"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3552-5144","authenticated-orcid":false,"given":"Ioannis U.","family":"Isaias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"141_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1055\/s-0034-1381733","volume":"34","author":"F Holtbernd","year":"2014","unstructured":"Holtbernd, F. & Eidelberg, D. The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes. Semin. Neurol. 34, 202\u2013209 (2014).","journal-title":"Semin. Neurol."},{"key":"141_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mds.26907","volume":"32","author":"AP Strafella","year":"2017","unstructured":"Strafella, A. P. et al. Molecular imaging to track Parkinson\u2019s disease and atypical parkinsonisms: new imaging frontiers. Mov. Disord. 32, 181\u2013192 (2017).","journal-title":"Mov. Disord."},{"key":"141_CR3","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"141_CR4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670\u2013676 (2008).","journal-title":"Neurology"},{"key":"141_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"141_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"141_CR7","doi-asserted-by":"crossref","unstructured":"Meyer, P. T., Frings, L., Rucker, G. & Hellwig, S. 18)F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment. J. Nucl. Med. 58, 1888\u20131898 (2017).","DOI":"10.2967\/jnumed.116.186403"},{"key":"141_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","volume":"9","author":"CC Tang","year":"2010","unstructured":"Tang, C. C. et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 9, 149\u2013158 (2010).","journal-title":"Lancet Neurol."},{"key":"141_CR9","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1212\/WNL.0b013e31826c1b0a","volume":"79","author":"S Hellwig","year":"2012","unstructured":"Hellwig, S. et al. [(1)(8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 79, 1314\u20131322 (2012).","journal-title":"Neurology"},{"key":"141_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.parkreldis.2012.01.009","volume":"18","author":"S Orimo","year":"2012","unstructured":"Orimo, S., Suzuki, M., Inaba, A. & Mizusawa, H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson\u2019s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 18, 494\u2013500 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"141_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jbi.2005.02.008","volume":"38","author":"TA Lasko","year":"2005","unstructured":"Lasko, T. A., Bhagwat, J. G., Zou, K. H. & Ohno-Machado, L. The use of receiver operating characteristic curves in biomedical informatics. J. Biomed. Inf. 38, 404\u2013415 (2005).","journal-title":"J. Biomed. Inf."},{"key":"141_CR12","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000005161","volume":"90","author":"A Pilotto","year":"2018","unstructured":"Pilotto, A. et al. Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. Neurology 90, e1029\u2013e1037 (2018).","journal-title":"Neurology"},{"key":"141_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2967\/jnumed.111.089946","volume":"52","author":"NI Bohnen","year":"2011","unstructured":"Bohnen, N. I. et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J. Nucl. Med. 52, 848\u2013855 (2011).","journal-title":"J. Nucl. Med."},{"key":"141_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3233\/JPD-150583","volume":"5","author":"C Tard","year":"2015","unstructured":"Tard, C. et al. Hypometabolism in posterior and temporal areas of the brain is associated with cognitive decline in Parkinson\u2019s disease. J. Parkinsons Dis. 5, 569\u2013574 (2015).","journal-title":"J. Parkinsons Dis."},{"key":"141_CR15","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2967\/jnumed.115.159822","volume":"56","author":"S Hellwig","year":"2015","unstructured":"Hellwig, S. et al. 18F-FDG PET is an early predictor of overall survival in suspected atypical parkinsonism. J. Nucl. Med. 56, 1541\u20131546 (2015).","journal-title":"J. Nucl. Med."},{"key":"141_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jns.2011.06.028","volume":"310","author":"K Witt","year":"2011","unstructured":"Witt, K. et al. Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson\u2019s disease. J. Neurol. Sci. 310, 261\u2013266 (2011).","journal-title":"J. Neurol. Sci."},{"key":"141_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archneurol.2010.260","volume":"68","author":"JM Bronstein","year":"2011","unstructured":"Bronstein, J. M. et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch. Neurol. 68, 165 (2011).","journal-title":"Arch. Neurol."},{"key":"141_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/ene.13206","volume":"24","author":"JS Kim","year":"2017","unstructured":"Kim, J. S. et al. Normal \u2018heart\u2019 in Parkinson\u2019s disease: is this a distinct clinical phenotype? Eur. J. Neurol. 24, 349\u2013356 (2017).","journal-title":"Eur. J. Neurol."},{"key":"141_CR19","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/mds.23338","volume":"25","author":"H Nagayama","year":"2010","unstructured":"Nagayama, H. et al. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov. Disord. 25, 1744\u20131747 (2010).","journal-title":"Mov. Disord."},{"key":"141_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00401-005-1013-9","volume":"110","author":"M Sone","year":"2005","unstructured":"Sone, M., Yoshida, M., Hashizume, Y., Hishikawa, N. & Sobue, G. alpha-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Acta Neuropathol. 110, 19\u201326 (2005).","journal-title":"Acta Neuropathol."},{"key":"141_CR21","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.jacc.2010.01.014","volume":"55","author":"AF Jacobson","year":"2010","unstructured":"Jacobson, A. F. et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J. Am. Coll. Cardiol. 55, 2212\u20132221 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"141_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12350-015-0387-x","volume":"23","author":"MJ Henzlova","year":"2016","unstructured":"Henzlova, M. J., Duvall, W. L., Einstein, A. J., Travin, M. I. & Verberne, H. J. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J. Nucl. Cardiol. 23, 606\u2013639 (2016).","journal-title":"J. Nucl. Cardiol."},{"key":"141_CR23","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s00259-010-1491-4","volume":"37","author":"A Flotats","year":"2010","unstructured":"Flotats, A. et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur. J. Nucl. Med. Mol. Imaging 37, 1802\u20131812 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"141_CR24","first-page":"1326","volume":"17","author":"A Stefanelli","year":"2013","unstructured":"Stefanelli, A., Treglia, G., Bruno, I., Rufini, V. & Giordano, A. Pharmacological interference with 123I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice? Eur. Rev. Med. Pharmacol. Sci. 17, 1326\u20131333 (2013).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"141_CR25","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.neuroimage.2005.03.012","volume":"26","author":"T Eckert","year":"2005","unstructured":"Eckert, T. et al. FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage 26, 912\u2013921 (2005).","journal-title":"NeuroImage"},{"key":"141_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1148\/radiology.198.3.8628880","volume":"198","author":"JH Burdette","year":"1996","unstructured":"Burdette, J. H., Minoshima, S., Vander Borght, T., Tran, D. D. & Kuhl, D. E. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology 198, 837\u2013843 (1996).","journal-title":"Radiology"},{"key":"141_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00259-011-1963-1","volume":"39","author":"K Nakajima","year":"2012","unstructured":"Nakajima, K. et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur. J. Nucl. Med. Mol. Imaging 39, 113\u2013119 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"141_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-019-0250-2","volume":"6","author":"J Brumberg","year":"2019","unstructured":"Brumberg, J. et al. Imaging cardiac sympathetic innervation with MIBG: linear conversion of the heart-to-mediastinum ratio between different collimators. EJNMMI Phys. 6, 12 (2019).","journal-title":"EJNMMI Phys."},{"key":"141_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/archneur.1997.00550200007003","volume":"54","author":"I Litvan","year":"1997","unstructured":"Litvan, I. et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch. Neurol. 54, 937\u2013944 (1997).","journal-title":"Arch. Neurol."},{"key":"141_CR30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archneur.55.7.969","volume":"55","author":"I Litvan","year":"1998","unstructured":"Litvan, I. et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch. Neurol. 55, 969\u2013978 (1998).","journal-title":"Arch. Neurol."},{"key":"141_CR31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/brain\/awf080","volume":"125","author":"AJ Hughes","year":"2002","unstructured":"Hughes, A. J., Daniel, S. E., Ben-Shlomo, Y. & Lees, A. J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861\u2013870 (2002).","journal-title":"Brain"},{"key":"141_CR32","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/mds.27125","volume":"32","author":"P Turcano","year":"2017","unstructured":"Turcano, P. et al. Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010. Mov. Disord. 32, 1439\u20131446 (2017).","journal-title":"Mov. Disord."},{"key":"141_CR33","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/brain\/awq123","volume":"133","author":"H Ling","year":"2010","unstructured":"Ling, H. et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133, 2045\u20132057 (2010).","journal-title":"Brain"},{"key":"141_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496\u2013503 (2013).","journal-title":"Neurology"},{"key":"141_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00259-018-4111-3","volume":"46","author":"S Hellwig","year":"2019","unstructured":"Hellwig, S. et al. Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [(18)F]FDG PET. Eur. J. Nucl. Med. Mol. Imaging 46, 312\u2013323 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"141_CR36","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00259-009-1264-0","volume":"36","author":"A Varrone","year":"2009","unstructured":"Varrone, A. et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur. J. Nucl. Med. Mol. Imaging 36, 2103\u20132110 (2009).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"141_CR37","first-page":"1238","volume":"36","author":"S Minoshima","year":"1995","unstructured":"Minoshima, S., Frey, K. A., Koeppe, R. A., Foster, N. L. & Kuhl, D. E. A diagnostic approach in Alzheimer\u2019s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 36, 1238\u20131248 (1995).","journal-title":"J. Nucl. Med."},{"key":"141_CR38","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1007\/s00259-010-1545-7","volume":"37","author":"E Bombardieri","year":"2010","unstructured":"Bombardieri, E. et al. 131I\/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur. J. Nucl. Med. Mol. Imaging 37, 2436\u20132446 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00141-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T03:05:00Z","timestamp":1670295900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00141-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1038\/s41531-020-00141-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.B., N.S., G.B., L.F., J.V., C.L., W.H.J., and I.U.I. report no conflict of interest. P.T.M. reports personal fees from GE and Philips, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}